143 related articles for article (PubMed ID: 6431436)
1. Clinical patterns of hemophilic patients who develop inhibitors.
McMillan CW
Prog Clin Biol Res; 1984; 150():31-44. PubMed ID: 6431436
[TBL] [Abstract][Full Text] [Related]
2. [Transient inhibitors developed in two cases of hemophilia A].
Fujiwara F; Kanoh G; Ogawa H; Takaya K; Hibi S; Shima M; Yoshioka A; Imashuku S
Rinsho Ketsueki; 1997 Dec; 38(12):1263-8. PubMed ID: 9455145
[TBL] [Abstract][Full Text] [Related]
3. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
[TBL] [Abstract][Full Text] [Related]
4. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
[TBL] [Abstract][Full Text] [Related]
6. Experience with factor VIII: C inhibitors and acquired von Willebrand's disease in an adult at Ramathibodi Hospital.
Angchaisuksiri P; Atichartakarn V; Pathepchotiwong K; Jootar S; Ungkanont A; Chuncharunee S
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():152-8. PubMed ID: 7886560
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
8. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor treatment using unactivated prothrombin complex concentrates: the Pennsylvania experience--1978-1982.
Eyster ME; Spero JA; Catalano PM; Gill FM; Lusch CJ; Kajani MK; Barron LE; DeGreen HP; Shapiro SS; Lewis JH
Prog Clin Biol Res; 1984; 150():309-22. PubMed ID: 6431435
[TBL] [Abstract][Full Text] [Related]
10. The effect of naturally occurring antibodies to factor VIII on an immunoradiometric assay for factor VIII coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIII inhibit.
Brown JE; Carton CL; Hougie C
J Lab Clin Med; 1981 Jan; 97(1):65-71. PubMed ID: 6778942
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
[TBL] [Abstract][Full Text] [Related]
12. The management of factor VIII inhibitors in non-hemophilic patients.
Green D
Prog Clin Biol Res; 1984; 150():337-52. PubMed ID: 6431438
[TBL] [Abstract][Full Text] [Related]
13. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
Scheibel E; Ingerslev J; Dalsgaard-Nielsen J; Stenbjerg S; Knudsen JB
Thromb Haemost; 1987 Dec; 58(4):1049-52. PubMed ID: 3127918
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.
Mauser-Bunschoten EP; Rosendaal FR; Nieuwenhuis HK; Roosendaal G; Briët E; van den Berg HM
Thromb Haemost; 1994 Jun; 71(6):703-6. PubMed ID: 7974335
[TBL] [Abstract][Full Text] [Related]
15. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
16. Treatment of anti-factor VIII antibodies.
Blatt PM; White GC; McMillan CW; Roberts HR
Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
[TBL] [Abstract][Full Text] [Related]
17. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
18. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
Goodeve AC; Williams I; Bray GL; Peake IR
Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
[TBL] [Abstract][Full Text] [Related]
19. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
Duncan E; Collecutt M; Street A
Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of factors which affect the measurement of factor VIII inhibitor by Bethesda method].
Takahashi Y; Arai M; Fukutake K
Rinsho Byori; 1996 May; 44(5):449-55. PubMed ID: 8676565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
